Cardiol Therapeutics Inc. CRDL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.52% | -2.20% | 9.62% | 6.33% | -24.60% |
| Total Depreciation and Amortization | -70.16% | -69.30% | -73.25% | -69.03% | 15.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.91% | 11.10% | -14.48% | -8.32% | 141.61% |
| Change in Net Operating Assets | 70.67% | 57.78% | 25.45% | 326.45% | -156.53% |
| Cash from Operations | 3.04% | 3.42% | 6.92% | 9.31% | -12.83% |
| Capital Expenditure | -78.02% | -105.63% | -11.54% | -2.62% | -32.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -78.02% | -105.63% | -11.54% | -2.62% | -32.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.00% | -33.33% | -33.33% | -33.33% | 9.09% |
| Issuance of Common Stock | 56.05% | 44.21% | -25.36% | 11,950.65% | 11,950.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 35.37% | 35.37% | 82.01% | -- | -- |
| Cash from Financing | 71.08% | 57.29% | -17.20% | 13,233.77% | 14,228.11% |
| Foreign Exchange rate Adjustments | -30.92% | -138.23% | -143.30% | 8.37% | 1.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 233.91% | 180.84% | -85.40% | 83.25% | 72.62% |